FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101404349> ?p ?o ?g. }

• W2101404349 endingPage "1458" @default.
• W2101404349 startingPage "1448" @default.
• W2101404349 abstract "Gefitinib (Iressa(R), ZD1839) is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks growth factor-mediated cell proliferation and extracellular signal-regulated kinases 1/2 (ERK1/2) signaling activation. Rad51 is an essential component of the homologous recombination repair pathway. High level of Rad51 expression has been reported in chemo- or radioresistant carcinomas. We hypothesized that gefitinib may enhance the effects of the alkylating agent cisplatin- or the antitumor antibiotic mitomycin C (MMC)-mediated cytotoxicity by decreasing ERK1/2 activation and Rad51 expression. Exposure of human non-small lung cancer cells to gefitinib decreased cisplatin- or MMC-elicited ERK1/2 activation and Rad51 protein induction. Neither cisplatin nor MMC treatment affected Rad51 messenger RNA (mRNA). However, gefitinib cotreatment with cisplatin or MMC significantly decreased Rad51 mRNA levels. In addition, gefitinib decreased cisplatin- or MMC-elicited Rad51 protein levels by increasing Rad51 protein instability. Enhancement of ERK1/2 signaling by constitutively active mitogen-activated protein kinase kinase 1/2 (MKK1/2-CA) increased Rad51 protein levels and protein stability in gefitinib and cisplatin or MMC cotreated cells. Moreover, the synergistic cytotoxic effects induced by gefitinib cotreatment with cisplatin or MMC were remarkably decreased by MKK1-CA-mediated enhancement of ERK1/2 activation. Depletion of endogenous Rad51 expression by si-Rad51 RNA transfection significantly enhanced lung cancer cell death upon treatment with cisplatin or MMC. We conclude that Rad51 protein protects lung cancer cells from synergistic cytotoxic effects induced by gefitinib and chemotherapeutic agents. Suppression of Rad51 expression may be a novel lung cancer therapeutic modality to overcome drug resistance to EGFR inhibitors and chemotherapeutic agents." @default.
• W2101404349 created "2016-06-24" @default.
• W2101404349 creator A5007652092 @default.
• W2101404349 creator A5022304365 @default.
• W2101404349 creator A5034784503 @default.
• W2101404349 creator A5035739384 @default.
• W2101404349 creator A5051331142 @default.
• W2101404349 creator A5056680093 @default.
• W2101404349 creator A5081844814 @default.
• W2101404349 creator A5083183162 @default.
• W2101404349 date "2008-05-29" @default.
• W2101404349 modified "2023-09-25" @default.
• W2101404349 title "Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells" @default.
• W2101404349 cites W1965122158 @default.
• W2101404349 cites W1965904237 @default.
• W2101404349 cites W1966717845 @default.
• W2101404349 cites W1978872365 @default.
• W2101404349 cites W1985385147 @default.
• W2101404349 cites W1987345634 @default.
• W2101404349 cites W1995819749 @default.
• W2101404349 cites W1995839957 @default.
• W2101404349 cites W1996405087 @default.
• W2101404349 cites W1997019851 @default.
• W2101404349 cites W2001155346 @default.
• W2101404349 cites W2005274511 @default.
• W2101404349 cites W2006226567 @default.
• W2101404349 cites W2006299554 @default.
• W2101404349 cites W2007559737 @default.
• W2101404349 cites W2011881129 @default.
• W2101404349 cites W2014396605 @default.
• W2101404349 cites W2016003408 @default.
• W2101404349 cites W2019759754 @default.
• W2101404349 cites W2022039302 @default.
• W2101404349 cites W2028427446 @default.
• W2101404349 cites W2031010326 @default.
• W2101404349 cites W2034811411 @default.
• W2101404349 cites W2037139573 @default.
• W2101404349 cites W2041929141 @default.
• W2101404349 cites W2043696829 @default.
• W2101404349 cites W2045506022 @default.
• W2101404349 cites W2050648887 @default.
• W2101404349 cites W2058977958 @default.
• W2101404349 cites W2061335015 @default.
• W2101404349 cites W2064047613 @default.
• W2101404349 cites W2068581230 @default.
• W2101404349 cites W2074699503 @default.
• W2101404349 cites W2080883315 @default.
• W2101404349 cites W2085117308 @default.
• W2101404349 cites W2086389702 @default.
• W2101404349 cites W2095169768 @default.
• W2101404349 cites W2095231498 @default.
• W2101404349 cites W2114725617 @default.
• W2101404349 cites W2120718661 @default.
• W2101404349 cites W2127101185 @default.
• W2101404349 cites W2128370098 @default.
• W2101404349 cites W2130177169 @default.
• W2101404349 cites W2130939448 @default.
• W2101404349 cites W2132139248 @default.
• W2101404349 cites W2132392721 @default.
• W2101404349 cites W2133712354 @default.
• W2101404349 cites W2138178697 @default.
• W2101404349 cites W2143780735 @default.
• W2101404349 cites W2145653040 @default.
• W2101404349 cites W2145842917 @default.
• W2101404349 cites W2147037760 @default.
• W2101404349 cites W2149220596 @default.
• W2101404349 cites W2151886926 @default.
• W2101404349 cites W2152755651 @default.
• W2101404349 cites W2153534791 @default.
• W2101404349 cites W2158179945 @default.
• W2101404349 cites W2158380484 @default.
• W2101404349 cites W2162724777 @default.
• W2101404349 cites W2165848530 @default.
• W2101404349 cites W2166592024 @default.
• W2101404349 cites W2167539266 @default.
• W2101404349 cites W2172247857 @default.
• W2101404349 cites W2236524872 @default.
• W2101404349 cites W4296978003 @default.
• W2101404349 doi "https://doi.org/10.1093/carcin/bgn130" @default.
• W2101404349 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18544565" @default.
• W2101404349 hasPublicationYear "2008" @default.
• W2101404349 type Work @default.
• W2101404349 sameAs 2101404349 @default.
• W2101404349 citedByCount "58" @default.
• W2101404349 countsByYear W21014043492012 @default.
• W2101404349 countsByYear W21014043492013 @default.
• W2101404349 countsByYear W21014043492014 @default.
• W2101404349 countsByYear W21014043492015 @default.
• W2101404349 countsByYear W21014043492016 @default.
• W2101404349 countsByYear W21014043492017 @default.
• W2101404349 countsByYear W21014043492018 @default.
• W2101404349 countsByYear W21014043492019 @default.
• W2101404349 countsByYear W21014043492020 @default.
• W2101404349 countsByYear W21014043492021 @default.
• W2101404349 crossrefType "journal-article" @default.
• W2101404349 hasAuthorship W2101404349A5007652092 @default.
• W2101404349 hasAuthorship W2101404349A5022304365 @default.
• W2101404349 hasAuthorship W2101404349A5034784503 @default.

• next